We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.03%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$155M
AUM Growth
+$8.11M
Cap. Flow
+$10.2M
Cap. Flow %
6.57%
Top 10 Hldgs %
70.21%
Holding
70
New
6
Increased
8
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
ELUT icon
Elutia
ELUT
+$8.01M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$1.6M
3
BDSX icon
Biodesix
BDSX
+$965K
4
TSVT
2seventy bio
TSVT
+$873K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$828K

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.84M
2
BMY icon
Bristol-Myers Squibb
BMY
+$1.76M
3
BLUE
bluebird bio
BLUE
+$539K
4
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$410K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$349K

Sector Composition

Rank Sector Weight
1 Healthcare 96.09%
2 Energy 2.08%
3 Consumer Staples 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVV icon
26
Ovintiv
OVV
$16.2B
$1.15M 0.74%
34,200
– –
CYTK icon
27
Cytokinetics
CYTK
$10.7B
$1.14M 0.74%
25,000
– –
GOSS icon
28
Gossamer Bio
GOSS
$68.9M
$1.13M 0.73%
100,000
+60,000
+150% +$713K
AMRN
29
Amarin Corp
AMRN
$285M
$1.01M 0.65%
15,000
– –
CORT icon
30
Corcept Therapeutics
CORT
$9.83B
$990K 0.64%
50,000
– –
VNDA icon
31
Vanda Pharmaceuticals
VNDA
$320M
$941K 0.61%
60,000
-20,000
-25% -$349K
BLUE
32
DELISTED
bluebird bio
BLUE
$839K 0.54%
4,200
-2,285
-35% -$539K
PGNY icon
33
Progyny
PGNY
$2.49B
$755K 0.49%
15,000
– –
CCXI
34
DELISTED
ChemoCentryx, Inc.
CCXI
$728K 0.47%
20,000
-5,000
-20% -$176K
TSVT
35
DELISTED
2seventy bio
TSVT
$718K 0.46%
+27,999
New +$873K
CGEM icon
36
Cullinan Oncology
CGEM
$1.08B
$696K 0.45%
45,114
– –
PXD
37
DELISTED
Pioneer Natural Resource Co.
PXD
$691K 0.45%
3,800
– –
ZNTL icon
38
Zentalis Pharmaceuticals
ZNTL
$357M
$672K 0.43%
8,000
– –
AVEO
39
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$657K 0.42%
140,000
+100,000
+250% +$620K
NARI
40
DELISTED
Inari Medical, Inc. Common Stock
NARI
$639K 0.41%
7,000
– –
APLS
41
DELISTED
Apellis Pharmaceuticals
APLS
$567K 0.37%
12,000
– –
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
$529K 0.34%
40,000
– –
CFRX
43
DELISTED
ContraFect Corporation
CFRX
$526K 0.34%
2,500
– –
VTYX
44
DELISTED
Ventyx Biosciences
VTYX
$497K 0.32%
+25,000
New +$474K
XNCR icon
45
Xencor
XNCR
$1.39B
$493K 0.32%
12,300
– –
IRTC icon
46
iRhythm Holdings
IRTC
$3.66B
$471K 0.3%
4,000
– –
FOLD
47
DELISTED
Amicus Therapeutics
FOLD
$439K 0.28%
38,000
– –
GTHX
48
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$408K 0.26%
40,000
– –
TPTX
49
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$382K 0.25%
8,000
– –
SLNO
50
DELISTED
Soleno Therapeutics
SLNO
$360K 0.23%
58,460
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Birchview Capital held 70 positions worth $155M, up 5.5% from $147M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital deployed $10.2M of net new capital in Q4 2021, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Inhibrx, Inc. Common Stock: 40,000 shares worth $1.75M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $1.76M trimmed.

  • Birchview Capital's largest Q4 2021 buy was Inhibrx, Inc. Common Stock: 40,000 shares worth $1.75M.
  • Birchview Capital added most to Elutia in Q4 2021, an estimated $8.01M increase.
  • Birchview Capital's biggest Q4 2021 reduction was Bristol-Myers Squibb, cutting an estimated $1.76M.
  • Birchview Capital fully exited Acceleron Pharma in Q4 2021, selling an estimated $1.84M.
  • Birchview Capital's ten largest holdings make up 70% of its $155M portfolio in Q4 2021.
  • Birchview Capital opened 6 new positions and closed 3 in Q4 2021.
  • Birchview Capital's portfolio value rose 5.5% quarter-over-quarter to $155M.

Based on Birchview Capital's 13F filing for Q4 2021, filed 14 Feb 2022.